PMGC HOLDINGS INC. Capitalized Costs of Unproved Properties Excluded from Amortization, Period Cost
PMGC HOLDINGS INC. (ELAB) reported Capitalized Costs of Unproved Properties Excluded from Amortization, Period Cost of $4.31 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortization · last filed 2024-05-15
- PMGC HOLDINGS INC. capitalized costs of unproved properties excluded from amortization, period cost for the quarter ending 2024-03-31 was $4.31K, a 100.14% increase year-over-year.
- PMGC HOLDINGS INC. capitalized costs of unproved properties excluded from amortization, period cost for the quarter ending 2023-03-31 was $2.15K.
| Period end | Capitalized Costs of Unproved Properties Excluded from Amortization, Period Cost 3 month |
|---|---|
| 2024-03-31 | $4.31K 10-Q · filed 2024-05-15 |
| 2023-03-31 | $2.15K 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B |